Wednesday, July 8, 2026

Patent intelligence · US

US 8039001

Therapeutic and prophylactic vaccine for the treatment and prevention of papillomavirus infection

granted A61KA61K2039/5256A61K2039/5258A61K2039/585
Status granted
Linked drugs 2
Pipeline programs 6
Years to expiry 5
Applicant portfolio 8,292
Patent details — US 8039001

Quick answer

US 8039001 (Therapeutic and prophylactic vaccine for the treatment and prevention of papillomavirus infection) is held by The Regents of the University of Colorado, a Body Corporate. Status: granted. Granted Oct 18, 2011. Expires Oct 13, 2031 (5 years remaining) — relevant for patent-cliff and LOE planning.

Key facts

Grant date
Expiration
Claims
29
CPC classes
A61K, A61K2039/5256, A61K2039/5258, A61K2039/585, A61K39/12, A61P

More from The Regents of the University of Colorado, a Body Corporate

Related pharmaceutical patents in our USPTO index.

  1. US 12428463

    Chimeric antigen receptors targeting abnormal glycobiology

    THE REGENTS OF THE UNIVERSITY OF MICHIGAN · Expires Sep 25, 2045

    granted
  2. US 12427148

    Cancer treatment targeted to tumor adaptive responses to protein synthesis stress

    The Regents of the University of California · Expires Sep 25, 2045

    granted
  3. US 12428416

    ERK inhibitors and uses thereof

    The Regents of the University of California · Expires Sep 25, 2045

    granted
  4. US 12427151

    Compositions and method of treating cancer

    The Regents of the University of California · Expires Sep 25, 2045

    granted
  5. US 12427197

    Methods of producing cobalt nanoparticles and hollow metal nanospheres

    The Regents of the University of California · Expires Sep 25, 2045

    granted
  6. US 12428489

    Human PD-L2 antibodies and methods of use therefor

    The Board of Regents of the University of Texas System · Expires Sep 25, 2045

    granted
  7. US 12427155

    Treatment for tau-related diseases

    The Regents of the University of California · Expires Sep 25, 2045

    granted
  8. US 12428455

    Dominant negative CEBPB and CEBPD proteins and methods of use for decreasing viability of neoplastic cells

    The Regents of the University of California · Expires Sep 25, 2045

    granted

Frequently asked questions

What is US patent 8039001?

US 8039001 (Therapeutic and prophylactic vaccine for the treatment and prevention of papillomavirus infection) is held by The Regents of the University of Colorado, a Body Corporate. Status: granted. Granted Oct 18, 2011. Expires Oct 13, 2031 (5 years remaining) — relevant for patent-cliff and LOE planning.

Who owns US 8039001?

The Regents of the University of Colorado, a Body Corporate is listed as the applicant in USPTO PatentsView records indexed by NovaPharmaNews. We track 8,292 pharmaceutical patents for this assignee.

When does US 8039001 expire?

Our index shows an expiration date of Oct 13, 2031 (5 years from today). Confirm material dates against USPTO, FDA Orange Book, or qualified counsel before contractual decisions.